Group 1 - The core viewpoint of the article highlights the financial performance and market position of BGM, which saw a stock price increase of 5.55% to $7.99 per share, with a total market capitalization of $1.47 billion as of August 18 [1] - As of March 31, 2025, BGM reported total revenue of $14.31 million, reflecting a year-on-year growth of 13.92%, while the net profit attributable to shareholders was a loss of $0.8612 million, a significant decrease of 307.79% compared to the previous year [1] - BGM, formerly known as Qilian International Holdings Group, is based in Chengdu, China, and focuses on innovative solutions in the biopharmaceutical, biorefining, and healthcare sectors [1] Group 2 - The company's product range includes tetracycline raw materials, licorice preparations, and crude heparin sodium, which are essential for both human pharmaceuticals and the global livestock industry [1] - Tetracycline raw materials are used not only for producing human antibiotics but also support the safety of poultry and seafood in the global farming sector [1] - Crude heparin sodium is processed by downstream companies into refined heparin sodium and injectable heparin sodium solutions, serving as a major anticoagulant [1]
博美集团上涨5.55%，报7.99美元/股，总市值14.70亿美元